EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has reported E.P.S. of $-0.55 for its first fiscal quarter (ending March 31) versus $-0.56 for the same period a year ago. For the latest four quarters through March 31, E.P.S. were $-1.82 versus $-2.73 for the same period a year ago.
Recent Price Action
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock declined by -2.6% on 5/8/24. The shares closed at $11.56. Moreover, this decline was accompanied by above average trading volume at 120% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -34.3% during the last week.
Current PriceTarget Research Rating
EYPT is expected to continue to be a modest Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
EyePoint Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. EyePoint Pharmaceuticals has a very low Appreciation Score of 15 but a very high Power Rating of 92, resulting in the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment